新闻室

February 8, 2021

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

2020年10月27日

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

2020年6月29日

Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More

2019年4月4日

Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies.  Read More

Septermber 4, 2018

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

2018年6月28日

Repligen选择Purolite Life Sciences作为新型高性能配基商业化合作伙伴。 阅读全文

2018年6月27日

Repligen宣布与Navigo Proteins达成下一代亲和配基独家合作开发协议。 阅读全文

2017年6月23日

Repligen Corporation与 Spectrum Inc. 宣布合并。 阅读全文

2016年12月15日

Repligen 收购 TangenX Technology Corporation。 阅读全文

2016年10月4日

Repligen 推出用于生物工艺强化的一次性使用 XCell™ ATF 系统。 阅读全文

2016年4月4日

Repligen 收购 Atoll GmbH。 阅读全文

February 12, 2021

GEN

February 10, 2021

Repligen and Navigo target next-wave COVID vaccines with affinity resin

America's Best Mid-size Companies
Repligen: #15

Navigo and Repligen Team on COVID-19 Vaccine Affinity Resin

Continuous Processing: A Step on the Way to Bioprocess 4.0

Repligen boosting single-use portfolio with Engineered Molding Technology buy

Repligen up on OPUS® and Gene Therapy Demand

GEN

Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application